ArticleCureus2025
Understanding the Dual Challenge: Adverse Drug Reactions and Adherence in Rheumatoid Arthritis Treatment.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe primary aim of this study was to investigate the real-world occurrence of various adverse drug reactions (ADRs) and assess medication adherence among patients using disease-modifying antirheumatic drugs (DMARDs). Additionally, the study sought to evaluate the degree of methotrexate intolerance among these patients.
methodsThis cross-sectional, observational study was conducted at a tertiary care hospital and involved 100 adult patients diagnosed with rheumatoid arthritis (RA) who were currently undergoing treatment with methotrexate. The study systematically recorded all adverse drug reactions reported by the patients as well as those identified through laboratory tests. Medication adherence was measured using the Compliance Questionnaire Rheumatology (CQR5) and both intentional and non-intentional non-adherence questionnaires. The methotrexate intolerance was assessed using the Methotrexate Intolerance Severity Score (MISS).
resultsOut of the total 74 reported ADRs, gastrointestinal were the most common, accounting for 62 (76.53%) of cases, followed by hematological problems at 13 (16.07%), with other types of ADRs comprising the remaining. Despite the prevalence of gastrointestinal ADRs, the study found high levels of medication adherence among the patients. Additionally, the methotrexate intolerance was relatively low, which may be attributed to the use of folic acid supplementation by all participants.
conclusionGastrointestinal adverse drug reactions were the most frequently observed side effects in this study. Despite these reactions, patients demonstrated a high level of adherence to methotrexate therapy. The factors contributing to this adherence- such as patient counseling, disease knowledge, or the duration of the disease- merit further investigation to understand their impact on treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.